Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
1Department of Ophthalmology, Faculty of Medicine, Oita University, Japan
2Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan
3Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L69 3BX, UK
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
Description
Recent clinical trials of the intravitreal injection of anti-VEGF agents (ranibizumab, bevacizumab) have shown excellent results in the treatment of angiogenic pathologies including choroidal neovascularization, proliferative diabetic retinopathy, and neovascular glaucoma. Bleeding from the retinal vessels or new vessels during a standard vitrectomy after intravitreal injection of bevacizumab (IVB) has been reported to occur significantly less frequently than that observed during a standard vitrectomy without bevacizumab therapy. IVB has also been reported to be effective in the regression of new vessels in PDR and neovascular glaucoma (NVG). This injection may provide us with sufficient time to treat these patients with retinal photocoagulation. In addition, it may also be used as an adjunctive therapy for a mitomycin C (MMC) trabeculectomy to treat NVG.
We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the mechanisms of the clinical effects of anti-VEGF drug therapy, as well as the evaluation of their outcomes. Ranibizumab is used worldwide for the treatment of age-related macular degeneration. We are particularly interested in articles describing the effect of other anti-VEGF drugs trials; mechanisms of the effect of anti-VEGF agents; evaluation of outcomes for macular edema, PDR, neovascular glaucoma, and other diseases. Potential topics include, but are not limited to:
- Mechanisms of the effect of anti-VEGF agents for angiogenic pathologies
- Pathological changes after the anti-VEGF therapies
- Evaluations of outcomes of anti-VEGF therapy for various ocular diseases
- OCT and angiographic images after anti-VEGF therapy
- New approach of anti-VEGF agents
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jop/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: